

National Board of Examinations

Question Paper Name :	DrNB Clinical Hematology Paper3
Subject Name :	DrNB Clinical Hematology Paper3
Creation Date :	2021-08-26 19:34:25
Duration :	180
Total Marks :	100
Display Marks:	No

DrNB Clinical Hematology Paper3

Group Number :	1
Group Id :	327187448
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100
Is this Group for Examiner? :	No

DrNB Clinical Hematology Paper3

Section Id :	327187451
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory

Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Sub-Section Number :	1
Sub-Section Id :	327187455
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 3271873001 Question Type : SUBJECTIVE

Correct Marks : 10

Acute myeloid leukemia in elderly:

- a) Risk stratification. [3]
- b) Briefly discuss non-transplant treatment options. [4]
- c) Reduce intensity Conditioning Transplant. [3]

Question Number : 2 Question Id : 3271873002 Question Type : SUBJECTIVE

Correct Marks : 10

Down syndrome associated AML:

- a) Diagnostic workup and prognosis. [5]
- b) Therapy recommended for acute megakaryoblastic leukemia (AMKL). [5]

Question Number : 3 Question Id : 3271873003 Question Type : SUBJECTIVE

Correct Marks : 10

Newer Anticoagulant:

- a) Various DOACs in clinical practise. [5]
- b) Heparin induced thrombocytopenia and its management. [5]

Question Number : 4 Question Id : 3271873004 Question Type : SUBJECTIVE

Correct Marks : 10

Chronic lymphoblastic leukemia:

- a) What is monoclonal B lymphocytosis? [2]
- b) How to diagnose and prognosticate CLL? [4]
- c) Current treatment guidelines. [4]

Question Number : 5 Question Id : 3271873005 Question Type : SUBJECTIVE

Correct Marks : 10

Monoclonal Antibodies:

- a) Inotuzumab ozogamicin: Its role in clinical practice. [5]
- b) Ponatinib in ph positive ALL. [5]

Question Number : 6 Question Id : 3271873006 Question Type : SUBJECTIVE

Correct Marks : 10

Pediatric acute lymphoblastic leukemia:

- a) Baseline risk stratification. [5]
- b) Whole transcriptome sequencing for the classification of acute lymphoblastic leukemia. [5]

Question Number : 7 Question Id : 3271873007 Question Type : SUBJECTIVE

Correct Marks : 10

Hemostasis:

- a) What are the various methods of developing Extended half life clotting factor products? [4]
- b) Role of Emicizumab for haemophilia A. [3]
- c) Afibrinogenemia: Presentation and diagnosis. [3]

Question Number : 8 Question Id : 3271873008 Question Type : SUBJECTIVE

Correct Marks : 10

Newer treatment options:

- a) Oral Azacitadine. [4]
- b) Inqovi (decitabine and cedazuridine). [3]
- c) Ivosidenib. [3]

Question Number : 9 Question Id : 3271873009 Question Type : SUBJECTIVE

Correct Marks : 10

Bleeding and thrombosis:

- a) DIC ISTH scoring system. [5]
- b) Vaccine-induced immune thrombotic thrombocytopenia (VITT). [5]

Question Number : 10 Question Id : 3271873010 Question Type : SUBJECTIVE

Correct Marks : 10

COVID-19 and hematology patients:

- a) Risk of severity of SARS-Cov-2 disease and adverse outcomes in Hematology patients. [5]
- b) Vaccine guidelines for hematology patients. [5]